SCHEDULE: Adage Capital Discloses 4.97% Stake in Cidara
Beneficial Ownership Disclosure
Adage Capital Management, L.P. and its principals have disclosed a 4.97% beneficial ownership stake in Cidara Therapeutics, Inc., holding 1,100,000 shares.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 1,100,000 shares of Cidara Therapeutics, Inc. Common Stock.
- This ownership represents 4.97% of the total outstanding shares of Cidara Therapeutics, Inc.
- The calculation of the percentage is based on an aggregate of 22,117,550 shares of Common Stock outstanding.
- The total shares outstanding include 12,969,823 shares as of May 5, 2025, and an additional 9,147,727 shares issued and sold through a prospectus filed on June 25, 2025, following the exercise of underwriters' over-allotment option.
Sentiment
Score: 5
Explanation: This filing is a routine disclosure of beneficial ownership and does not contain performance or forward-looking statements that would indicate a positive or negative sentiment. It is a factual report of an investment position.
Positives
- NA
Negatives
- NA
Risks
- This filing is a disclosure of beneficial ownership and does not detail specific company risks. The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
The disclosure of a significant stake by an investment management firm like Adage Capital Management in a biotechnology company such as Cidara Therapeutics is a common occurrence, reflecting institutional interest in the sector's growth potential and specific company prospects. Such investments can signal confidence in the company's long-term strategy or pipeline.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake can provide confidence or signal institutional interest in the company, potentially influencing market perception and trading activity.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2025-05-05 | Date as of which 12,969,823 shares of Common Stock were reported outstanding in the Company's Quarterly Report on Form 10-Q. |
| 2025-05-08 | Date the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, was filed with the SEC. |
| 2025-06-25 | Date the Company's Prospectus was filed pursuant to Rule 424(b)(5) with the SEC, detailing the issuance of 9,147,727 shares. |
| 2025-06-26 | Date of the Company's press release describing the share issuance and completion of the offering. |
| 2025-06-30 | Date of event which requires the filing of this statement. |
| 2025-08-12 | Signature date of the Schedule 13G Amendment No. 1 filing. |
Keywords
Cidara Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Investment Management, Common Stock, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.